Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ESO-SPARE: Esophagus Sparring Radiotherapy for Thoracic and Cervical Metastatic Spinal Cord Compression. A Randomized Phase III Study.

NCT05109819 is registered in ClinicalTrials.gov with Herlev Hospital as lead sponsor.

NCT NCT05109819
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05109819 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ESO-SPARE: Esophagus Sparring Radiotherapy for Thoracic and Cervical Metastatic Spinal Cord Compression. A Randomized Phase III Study.
Lead sponsor
Herlev Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
May 20, 2021
Completion date
May 31, 2024
Enrollment
200 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

esophagitis, metastatic spinal cord compression, patient reported outcome measures, radiation toxicity